Abstract 5811: ABL103, a bispecific antibody targeting B7-H4 and 4-1BB, shows synergistic immune responses with combination of pembrolizumab in the immunosuppressive tumor microenvironment
Year: 2025
Type: conference-abstract
Source: Cancer Research
Institution: ABL Bio (South Korea)
Language: English
Subfield: Oncology
Field: Medicine
Domain: Health Sciences
Open Access status: closed
OpenAlex ID: W4409631486